AXIM® Biotechnologies Nutraceutical Division Announces Cannabinoid-Based Wellness Gum Product Line at Benzinga Cannabis Capital Conference NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development, announced...

AXIM® Biotechnologies Files New U.S. Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today announced...

AXIM® Biotechnologies, Inc. Nutraceutical Division Receives Purchase Order for 50,000 Boxes of the Company’s Proprietary CBD-Based Chewing Gum NEW YORK, April 23, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today...

AXIM Biotech Announces the Production of CanChew Plus™, the Next Generation Controlled Release CBD Chewing Gum NEW YORK, March 01, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, began production of CanChew Plus™, the next...

Medical Marijuana, Inc. Investment – AXIM Biotech – Lays Out Powerhouse IP Pipeline, Cannabinoid R&D in Interview SAN DIEGO, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Medical Marijuana, Inc. (OTC Pink:MJNA) is proud to announce to the public and its shareholders that its portfolio investment, AXIM® Biotechnologies,...